Show simple item record

dc.contributor.authorPeters, S
dc.contributor.authorScherpereel, A
dc.contributor.authorCornelissen, R
dc.contributor.authorOulkhouir, Y
dc.contributor.authorGreillier, L
dc.contributor.authorKaplan, MA
dc.contributor.authorTalbot, T
dc.contributor.authorMonnet, I
dc.contributor.authorHiret, S
dc.contributor.authorBaas, P
dc.contributor.authorNowak, AK
dc.contributor.authorFujimoto, N
dc.contributor.authorTsao, AS
dc.contributor.authorMansfield, AS
dc.contributor.authorPopat, S
dc.contributor.authorZhang, X
dc.contributor.authorHu, N
dc.contributor.authorBalli, D
dc.contributor.authorSpires, T
dc.contributor.authorZalcman, G
dc.date.accessioned2022-04-27T12:14:05Z
dc.date.available2022-04-27T12:14:05Z
dc.date.issued2022-02-03
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2022en
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5100
dc.identifier.eissn1569-8041en_US
dc.identifier.eissn1569-8041
dc.identifier.doi10.1016/j.annonc.2022.01.074en_US
dc.identifier.doi10.1016/j.annonc.2022.01.074
dc.description.abstract<h4>Background</h4>In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up.<h4>Patients and methods</h4>Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs).<h4>Results</h4>With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61-0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation.<h4>Conclusions</h4>With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.titleFirst-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.en
dc.typeJournal Article
dcterms.dateAccepted2022-01-24
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1016/j.annonc.2022.01.074en
rioxxterms.licenseref.startdate2022-02-03
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamThoracic Oncology
dc.contributor.icrauthorPopat, Sanjayen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/